ArticleAddiction (Abingdon, England)2025
Quantity of delta-9-tetrahydrocannabinol consumption and cannabis use disorder among daily cannabis consumers.
Article in Addiction (Abingdon, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Phytocannabinoids and Male Fertility: Implications ofPlants (Basel, Switzerland) · 2026Review
- THC induced similar physiological effects on HIV transgenic rats and their controls without affecting HIV-induced deficits in effortful motivation.Journal of cannabis research · 2026Article
- Enhancing data compatibility in an evolving landscape: Medical cannabis and polysubstance use protocols in the PhenX Toolkit.Drug and alcohol dependence · 2026Article
- Motion and form perception in healthy individuals with adolescent cannabis use.Frontiers in psychiatry · 2026Article
- Investigating Links Between Prenatal Cannabis Exposure and Brain Development Using Magnetic Resonance Imaging Techniques: A Narrative Review.Biological psychiatry global open science · 2026Review
- Self-titration of cannabis consumption: An epidemiological perspective.Journal of psychiatric research · 2025Article
- High potency cannabis flower use is associated with heavier consumption and risk for cannabis use disorder among young adults in California, United States.Addiction (Abingdon, England) · 2025Article
- Beneficial and adverse effects of THC on cognition in the HIV-1 transgenic rat model: Importance of exploring task- and sex-dependent outcomes.Brain, behavior, and immunity · 2025Article
- Age Differences in Cannabis Consumption Patterns and in Associations Between Delta-9-Tetrahydrocannabinol Intake and Cannabis Use Disorders Among Adults with Daily Use.Cannabis and cannabinoid research · 2025Article
- Commentary on Borodovsky et al.: Enhancing research on THC quantification-Consumer awareness through accurate labelling.Addiction (Abingdon, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
BACKGROUND AND
aimsAmid escalating cannabis legalization and daily consumption in the United States (US), determining the risk of cannabis use disorder (CUD) and relevant consequences among daily consumers has become a public health priority. Understanding these risks requires valid assessment of the daily quantity of delta-9-tetrahydrocannabinol (THC) consumed and its relation to consequences. This study characterized daily cannabis consumption using a new method for estimating milligrams of THC (mgTHC), and examined the relationship between daily mgTHC and CUD severity in a large national sample of daily consumers. DESIGN, SETTING AND
participantsUS adult (aged 18+ years) daily cannabis consumers (n = 4134) completed a comprehensive online survey of cannabis consumption patterns (e.g. frequency, quantity, product types, potencies, administration methods) and Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) CUD criteria. MEASUREMENTS: The primary exposure was past-week daily mgTHC consumption, calculated from survey responses to queries about product type, amount and potency consumed and including adjustments for puff size and loss of THC from specific methods of administration. The primary outcomes were (1) number of CUD criteria (range = 0-11) and (2) CUD severity categories: none, mild, moderate, severe.
findingsMedian daily consumption was ~130 mgTHC, with substantial variability (25% ≤ 50 mg and 25% ≥ 290 mg). On average, participants endorsed 2.5 CUD criteria, and 65% met criteria for CUD (39% mild, 18% moderate, 8% severe). Greater daily mgTHC predicted higher CUD criteria count [beta
conclusionsAmong daily consumers of cannabis, there appears to be a positive relationship between the daily quantity of cannabis consumed (measured in milligrams of delta-9-tetrahydrocannabinol) and both the risk and severity of cannabis use disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.